FENC - Fennec Pharmaceuticals Tezkor likvidlik koeffitsiyenti

Fennec Pharmaceuticals (FENC) dori ishlab chiqarish va klinik sinovlarni tashqi hamkorlarga topshirib, global autsorsing orqali klinikalarga yetkazib berishni optimallashtiradi. Kimyoterapiya oluvchi bolalar uchun eshitish qobiliyatini himoya qilish vositasining bozorga chiqarilishidan so'ng, yangi molekulalar ishlab chiqish vaqtincha sekinlashdi. Biznes kuchli lobbiyga va qat'iy FDA ramkalari doirasida faoliyat yurituvchi PEDMARK patent himoyasiga tayanadi. 5.46 ko'rsatkichi bilan bog'liq bozor tendentsiyasi aktivning joriy narx harakatini aniq namoyish etadi.

Fennec (FENC) Tezkor likvidlik: 04.07.2022 - 29.10.2026 davri uchun

Fennec Pharmaceuticals kompaniyasining tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:

Narx grafigi Fennec Pharmaceuticals Inc|FENC - Adolatli qiymat konsensusi

- bozor kapitallashuvi statistikasi:

Bozor kapitallashuvi Fennec Pharmaceuticals Inc|FENC - Korxona qiymati

- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:

Bitta aksiya uchun sof aktivlar Fennec Pharmaceuticals|FENC - Kompaniyaning balans qiymati|Kapitallashuvning sof aktivlarga nisbati fennecpharma.com|FENC - Aktivlarning umumiy qiymati

- qarz va likvidlik bo'yicha ma'lumotlar:

Qarzning xususiy kapitalga nisbati Fennec Pharmaceuticals|FENC - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Fennec Pharmaceuticals Inc.|FENC - Kompaniyaning jamlangan qarzi|Balans kapitallashuviga qarzlar Fennec Pharmaceuticals Inc|FENC - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli qarzi Fennec Pharmaceuticals|Tezkor likvidlik fennecpharma.com

- foyda va bozor multiplikatorlari tafsilotlari:

FENC - Kompaniyaning sof foydasi

Kompaniyaning jamlanma tahlili:Fennec Pharmaceuticals Inc - FENC

Fennec Pharmaceuticals Inc. ishlab chiqargan mahsulot

Fennec Pharmaceuticals (FENC) ximioterapiya davrida bolalar eshitish a'zolarini himoya qilish segmentida monopol pozitsiyani saqlab qolgan holda, barqaror pul oqimini ta'minlamoqda. Ushbu tendentsiya tezkor koeffitsiyent hisob-kitobida aks etgan bo'lib, u zaxiralarni chiqarib tashlagan holda, naqd pul va debitorlik qarzlari yig'indisi orqali to'lov qobiliyatini baholaydi. Ushbu ko'rsatkich illikvid aktivlarni olib tashlash orqali majburiyatlarni bajarishning haqiqiy imkoniyatini ochib beradi. Acid-test koeffitsiyenti tahlili esa defolt himoyasi va kapital samaradorligi o'rtasidagi muvozanatni aniqlash imkonini beradi.

Asosiy raqobatchilar

Incyte Corp. (INCY) - Tezkor likvidlik|HUTCHMED Corp - Oraliq qoplash koeffitsiyenti|NUVB (Nuvation Bio Inc.) - Tezkor likvidlik koeffitsiyenti|Tezkor likvidlik koeffitsiyenti dayonebio.com|Tezkor likvidlik Monopar Therapeutics Inc. (MNPR)|Tezkor likvidlik INBX (Inhibrx)|I-Mab Biopharma - Tezkor likvidlik ko‘rsatkichi|Oraliq qoplash koeffitsiyenti HRTX|NVCT - Tezkor likvidlik|Shoshilinch likvidlik Coherus BioSciences Inc.|Corbus Pharmaceuticals Holdings (CRBP) - Tezkor likvidlik|Shoshilinch likvidlik koeffitsiyenti CRDF|BYSI (BeyondSpring Pharma) - Tezkor likvidlik koeffitsiyenti|Tezkor likvidlik ko‘rsatkichi BioAtla Corp (BCAB)|Tezkor likvidlik Lixte Biotechnology (LIXT)|CTXR - Shoshilinch likvidlik|Tezkor likvidlik Cellectar Biosciences, Inc. CLRB|BioLineRx Ltd - Tezkor likvidlik|CANF - Tezkor likvidlik|Shoshilinch likvidlik Aprea Therapeutics|KZIA: Tezkor likvidlik koeffitsiyenti|Kritik likvidlik Silexion Therapeutics SLXN|Tezkor likvidlik ko‘rsatkichi NCNA|Shoshilinch likvidlik Chimerix Inc. CMRX|Tezkor likvidlik ko‘rsatkichi CYCC (Cyclacel Pharmaceuticals Inc.)|GTHX (g1therapeutics.com) - Oraliq qoplash koeffitsiyenti|Kronos Bio, Inc. - Tezkor likvidlik ko‘rsatkichi|Oraliq likvidlik koeffitsiyenti KTRA (kintara.com)|Oncternal Therapeutics, Inc. - Tezkor likvidlik koeffitsiyenti|Oraliq qoplash koeffitsiyenti PRTG (Portage Biotech Inc)